In this article, published in MedTech Intelligence, TTP's head of Biosensing, Chris Dawson explores how manufacturers can adapt to this evolving landscape by:
- Refining device reliability and ease of use
- Leveraging automated testing and multi-physics modelling for accelerated development
- Prioritising human factors engineering to ensure seamless integration into users’ lives
With CGM devices now reaching broader markets, including OTC options and non-traditional users, the challenge lies in balancing innovation with practical solutions that drive adherence and market acceptance.
Read the article in MedTech Intelligence to uncover latest insights into how CGM technology is shaping the future of diabetes care and health management. Read the full article here
About TTP’s Biosensing Team
Specialising in the development of wearable and implantable biosensors, TTP’s Biosensing product development team deploys multidisciplinary teams, combining expert capabilities from electrochemistry and optics to human factors, mechanical design, software, electronics, wireless power and communications to deliver tailored solutions that meet the most demanding project requirements.
Partnering with us means working with experts who understand the CGM industry inside out. Whether navigating uncharted territories, supporting your next innovation or accelerating time to market, we solve complex challenges with engineering and scientific rigour, finding and retiring risks early to deliver high-impact, human-centred results. When your internal bandwidth is constrained, TTP is ready to deliver. With deep expertise and a 25-year track record, we provide the agility and expertise needed to ensure your commercial success. Find out more.
Read more how we are accelerating CGM product development.
